Molecular mechanisms of Ebola virus pathogenesis: Focus on cell death

Cell Death and Differentiation

Volumn 22, Issue 8, 2015, Pages 1250-1259

  Falasca, L ^a   Agrati, C ^a   Petrosillo, N ^a   Di Caro, A ^a   Capobianchi, M R ^a   Ippolito, G ^a   Piacentini, M ^a,b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; INTERFERON;

ADAPTIVE IMMUNITY; BLOOD CLOTTING; BLOOD VESSEL; CELL DEATH; CELL KILLING; CYTOKINE RELEASE; CYTOKINE STORM; CYTOPATHOGENIC EFFECT; DENDRITIC CELL; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; FILOVIRIDAE; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; INTRACELLULAR SIGNALING; KIDNEY; LUNG; LYMPHOCYTE; MACROPHAGE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPLEEN; VIRUS ENTRY; VIRUS PATHOGENESIS; METABOLISM; PATHOGENICITY; PHYSIOLOGY; VIROLOGY;

EBOLA VIRUS; FILOVIRIDAE;

CELL DEATH; DENDRITIC CELLS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MACROPHAGES;

EID: 84935696105     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.67     Document Type: Review

References (115)

1. Goeijenbier M, van Kampen JJ, Reusken CB, Koopmans MP, van Gorp EC. Ebola virus disease: a review on epidemiology, symptoms, treatment and pathogenesis. Neth J Med 2014; 72: 442-448.
2. Hoenen T, Groseth A, Falzarano D, Feldmann H. Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med 2006; 12: 206-215.
3. Mohan GS, Ye L, Li W, Monteiro A, Lin X, Sapkota B et al. Less is more: Ebola surface glycoprotein expression levels regulate virus production and infectivity. J Virol 2014; 89: 1205-1217.
4. Watanabe S, Noda T, Halfmann P, Jasenosky L, Kawaoka Y. Ebola virus (EBOV) VP24 inhibits transcription and replication of the EBOV genome. J Infect Dis 2007; 196: S284-S290.
5. Hoenen T, Biedenkopf N, Zielecki F, Jung S, Groseth A, Feldmann H et al. Oligomerization of Ebola virus VP40 is essential for particle morphogenesis and regulation of viral transcription. J Virol 2010; 84: 7053-7063.
6. Kuhn JH, Andersen KG, Baize S, Baò Y, Bavari S, Berthet N et al. Nomenclatureand database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014.Viruses 2014; 6: 4760-4799.
7. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377: 849-862.
8. Empig CJ, Goldsmith MA. Association of the caveola vesicular system with cellular entry by filoviruses. J Virol 2002; 76: 5266-5270.
9. Sanchez A. Analysis of filovirus entry into vero e6 cells, using inhibitors of endocytosis, endosomal acidification, structural integrity, and cathepsin (B and L) activity. J Infect Dis 2007; 196: S251-S258.
10. Nanbo A, Imai M, Watanabe S, Noda T, Takahashi K, Neumann G et al. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog 2010; 6: e1001121.
11. Saeed MF, Kolokoltsov AA, Albrecht T, Davey RA. Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog 2010; 6: e1001110.
12. Hunt CL, Kolokoltsov AA, Davey RA, Maury W. The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirus. J Virol 2011; 85: 334-347.
13. Saeed MF, Kolokoltsov AA, Freiberg AN, Holbrook MR, Davey RA. Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus. PLoS Pathog 2008; 4: e1000141.
14. Beniac DR, Melito PL, Devarennes SL, Hiebert SL, Rabb MJ, Lamboo LL et al. The organisation of Ebola virus reveals a capacity for extensive, modular polyploidy. PLoS One 2012; 7: e29608.
15. Aleksandrowicz P, Marzi A, Biedenkopf N, Beimforde N, Becker S, Hoenen T et al. Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. JID 2011; 204: S957-S967.
16. Takada A, Watanabe S, Ito H, Okazaki K, Kida H, Kawaoka Y. Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 2000; 278: 20-26.
17. Siljamäki E, Rintanen N, Kirsi M, Upla P, Wang W, Karjalainen M et al. Cholesterol dependence of collagen and echovirus 1 trafficking along the novel 21 integrin internalization pathway. PLoS One 2013; 8: e55465.
18. Hunt CL, Lennemann NJ, Maury W. Filovirus entry: a novelty in the viral fusion world. Viruses 2012; 4: 258-275.
19. Bavari S, Bosio CM, Wiegand E, Ruthel G, Will AB, Geisbert TW et al. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 2002; 195: 593-602.
20. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011; 477: 340-343.
21. Côté M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 2011; 477: 344-348.
22. Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A et al. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J 2012; 31: 1947-1960.
23. Adam B, Lins L, Stroobant V, Thomas A. Brasseur R Distribution of hydrophobic, residues is crucial for the fusogenic properties of the Ebola virus GP2 fusion peptide. J Virol 2004; 78: 2131-2136.
24. Brecher M, Schornberg KL, Delos SE, Fusco ML, Saphire EO, White JM. Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J Virol 2012; 86: 364-372.
25. Martinez O, Ndungo E, Tantral L, Miller EH, Leung LW, Chandran K et al. A mutation in the Ebola virus envelope glycoprotein restricts viral entry in a host species-and cell-typespecific manner. J Virol 2013; 87: 3324-3334.
26. Bray M, Hatfill S, Hensley L, Huggins JW. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol 2001; 125: 243-253.
27. Bray M, Mahanty S. Ebola hemorrhagic fever and septic shock. J Infect Dis 2003; 188: 1613-1617.
28. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003; 188: 1618-1629.
29. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163: 2347-2370.
30. Mahanty S, Gupta M, Paragas J, Bray M, Ahmed R, Rollin PE. Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection. Virology 2003; 312: 415-424.
31. Hutchinson KL, Rollin PE. Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J Infect Dis 2007; 196: S357-S363.
32. Ansari AA. Clinical features and pathobiology of Ebolavirus infection. J Autoimmun 2014; 55C: 1-9.
33. Misasi J, Sullivan NJ. Camouflage and misdirection: the full-on assault of Ebola virus disease. Cell 2014; 159: 477-486.
34. Harcourt BH, Sanchez A, Offermann MK. Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. J Virol 1999; 73: 3491-3496.
35. Gupta M, Mahanty S, Ahmed R, Rollin PE. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology 2001; 284: 20-25.
36. Basler CF, Wang X, Muhlberger E, Volchkov V, Paragas J, Klenk HD et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci USA 2000; 97: 12289-12294.
37. Prins KC, Cardenas WB, Basler CF. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol 2009; 83: 3069-3077.
38. Schumann M, Gantke T, Muhlberger E. Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J Virol 2009; 83: 8993-8997.
39. Reid SP, Valmas C, Martinez O, Sanchez FM, Basler CF. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol 2007; 81: 13469-13477.
40. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol 2014; 14: 36-49.
41. Platanias LC. Introduction: interferon signals: what is classical and what is nonclassical J Interferon Cytokine Res 2005; 25: 732.
42. Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, Lee Y et al. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 2009; 83: 1837-1844.
43. Neil SJ, Sandrin V, Sundquist WI, Bieniasz PD. An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2007; 2: 193-203.
44. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci USA 2009; 106: 2886-2891.
45. Wahl-Jensen V, Kurz S, Feldmann F, Buehler LK, Kindrachuk J, DeFilippis V et al. Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression. PLoS Negl Trop Dis 2011; 5: e1359.
46. Escudero-Perez B, Volchkova VA, Dolnik O, Lawrence P, Volchkov VE. Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog 2014; 10: e1004509.
47. Hensley LE, Young HA, Jahrling PB, Geisbert TW. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 2002; 80: 169-179.
48. Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, Bedjabaga I et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002; 128: 163-168.
49. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS et al. Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J Infect Dis 2014; 210: 558-566.
50. Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J, Sundstrom JB et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis 1999; 179: S188-S191.
51. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis 2010; 4: e837.
52. Martins K, Cooper C, Warren T, Wells J, Bell T, Raymond J et al. Characterization of clinical and immunological parameters during Ebola virus infection of rhesus macaques. Viral Immunol 2015; 28: 32-41.
53. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, Wagoner KD et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 2004; 78: 10370-10377.
54. Chaiyaratana W, Chuansumrit A, Atamasirikul K, Tangnararatchakit K. Serum ferritin levels in children with dengue infection. Southeast Asian J Trop Med Public Health 2008; 39: 832-836.
55. Barut S, Dincer F, Sahin I, Ozyurt H, Akkus M, Erkorkmaz U. Increased serum ferritin levels in patients with Crimean-Congo hemorrhagic fever: can it be a new severity criterion Int J Infect Dis 2010; 14: e50-e54.
56. Bosio CM, Aman MJ, Grogan C, Hogan R, Ruthel G, Negley D et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 2003; 188: 1630-1638.
57. Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, Pulendran B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 2003; 170: 2797-2801.
58. Martinez O, Johnson J, Manicassamy B, Rong L, Olinger GG, Hensley LE et al. Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cell Microbiol 2010; 12: 148-157.
59. Melanson VR, Kalina WV, Williams P. Ebola virus infection induces irregular dendritic cell gene expression. Viral Immunol 2015; 28: 42-50.
60. Lubaki NM, Ilinykh P, Pietzsch C, Tigabu B, Freiberg AN, Koup RA et al. The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains. J Virol 2013; 87: 7471-7485.
61. Warfield KL, Perkins JG, Swenson DL, Deal EM, Bosio CM, Aman MJ et al. Role of natural killer cells in innate protection against lethal Ebola virus infection. J Exp Med 2004; 200: 169-179.
62. Fuller CL, Ruthel G, Warfield KL, Swenson DL, Bosio CM, Aman MJ et al. NKp30-dependent cytolysis of filovirus-infected human dendritic cells. Cell Microbiol 2007; 9: 962-976.
63. Bradfute SB, Braun DR, Shamblin JD, Geisbert JB, Paragas J, Garrison A et al. Lymphocyte death in a mouse model of Ebola virus infection. J InfectDis 2007; 196: S296-S304.
64. Reed DS, Hensley LE, Geisbert JB, Jahrling PB, Geisbert TW. Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic fever in cynomolgus macaques. Viral Immunol 2004; 17: 390-400.
65. Marcenaro E, Carlomagno S, Pesce S, Moretta A, Sivori S. NK/DC crosstalk in anti-viral response. Adv ExpMed Biol 2012; 946: 95-308.
66. Wehner R, Dietze K, Bachmann M, Schmitz M. The bidirectional crosstalk between human dendritic cells and natural killer cells. J Innate Immun 2011; 3: 258-263.
67. McElroy AK, Akondy RS, Davis CW, Ellebedy AH, Mehta AK, Kraft CS et al. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci USA 112: 4719-4724.
68. Sobarzo A, Ochayon DE, Lutwama JJ, Balinandi S, Guttman O, Marks RS et al. Persistent immune responses after Ebola virus infection. N Engl J Med 2013 3 69: 492-493.
69. Cook JD, Lee JE. The secret life of viral entry glycoproteins: moonlighting in immune evasion. PLoS Pathog 2013; 9: e1003258.
70. Kindzelskii AL, Yang Z, Nabel GJ, Todd RF, Petty HR. Ebola virus secretory glycoprotein (sGP) diminishes Fc gamma RIIIB-to-CR3 proximity on neutrophils. J Immunol 2000; 164: 953-958.
71. Yang Z, Delgado R, Xu L, Todd RF, Nabel EG, Sanchez A et al. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 1998; 279: 1034-1037.
72. Mohan GS, Li W, Ye L, Compans RW, Yang C. Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog 2012; 8: e1003065.
73. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 2009; 7: 393-400.
74. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debre P et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999; 5: 423-426.
75. Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL et al. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol 2005; 175: 1184-1191.
76. Warfield KL, Olinger GG. Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever. J Biomed Biotechnol 2011; 2011: 984241.
77. Wong G, Richardson JS, Pillet S, Patel A, Qiu X, Alimonti J et al. Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates. Sci Transl Med 2012; 4: 158-146.
78. Bradfute SB, Warfield KL, Bavari S. Functional CD8+ T cell responses in lethal Ebola virus infection. J Immunol 2008; 180: 4058-4066.
79. Olejnik J, Alonso J, Schmidt KM, Yan Z, Wang W, Marzi A et al. Ebola virus does not block apoptotic signaling pathways. J Virol 2013; 87: 5384-5396.
80. Ray RB, Basu A, Steele R, Beyene A, McHowat J, Meyer K et al. Ebola virus glycoproteinmediated anoikis of primary human cardiac microvascular endothelial cells. Virology 2004; 321: 181-188.
81. Wahl-Jensen VM, Afanasieva TA, Seebach J, Ströher U, Feldmann H, Schnittler HJ. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol 2005; 79: 10442-10450.
82. Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun 2005; 73: 1907-1916.
83. Ashida H, Mimuro H, Ogawa M, Kobayashi T, Sanada T, Kim M et al. Cell death and infection: a double-edged sword for host and pathogen survival. J Cell Biol 2011; 195: 931-942.
84. Galluzzi L, Kroemer G. Necroptosis: a specialized pathway of programmed necrosis. Cell 2008; 135: 1161-1163.
85. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700-714.
86. Fisher-Hoch SP, Brammer TL, Trappier SG, Hutwagner LC, Farrar BB, Ruo SL et al. Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain. J Infec Dis 1992; 166: 753-763.
87. Johnson E, Jaax N, White J, Jahrling P. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol 1995; 76: 227-236.
88. Ryabchikova EI, Kolesnikova LV, Luchko SV. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis 1999; 179: S199-S202.
89. Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol 2015; 235: 153-174.
90. Kindrachuk J, Wahl-Jensen V, Safronetz D, Trost B, Hoenen T, Arsenault R et al. Ebola virus modulates transforming growth factor signaling and cellular markers of mesenchyme-like transition in hepatocytes. J Virol 2014; 88: 9877-9892.
91. Paessler S, Walker DH. Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol 2013; 8: 411-440.
92. Cowled C, Stewart CR, Likic VA, Friedländer MR, Tachedjian M, Jenkins KA et al. Characterisation of novel microRNAs in the Black flying fox (Pteropus alecto) by deep sequencing. BMC Genomics 2014; 15: 682.
93. Bauckman KA, Owusu-Boaitey N, Mysorekar IU. Selective autophagy: xenophagy. Methods 2014; 75: 120-127.
94. Mizumura K, Choi AM, Ryter SW. Emerging role of selective autophagy in human diseases. Front Pharmacol 2014; 5: 244.
95. Paulus GL, Xavier RJ. Autophagy and checkpoints for intracellular pathogen defense. Curr Opin Gastroenterol 2015; 31: 14-23.
96. Joven J, Guirro M, Mariné-Casadó R, Rodríguez-Gallego E, Menéndez JA. Autophagy is an inflammation-related defensive mechanism against disease. Adv Exp Med Biol 2014; 824: 43-59.
97. Sir D, Ou JH. Autophagy in viral replication and pathogenesis. Mol Cells 2010; 29: 1-7.
98. Deretic V. Autophagy in immunity and cell-autonomous defense against intracellular microbes. Immunol Rev 2011; 240: 92-104.
99. Orvedahl A, Alexander D, Tallóczy Z, Sun Q, Wei Y, Zhang W et al. HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe 2007; 1: 23-35.
100. Kyei GB, Dinkins C, Davis AS, Roberts E, Singh SB, Dong C et al. Autophagy pathway intersects with HIV1 biosynthesis and regulates viral yields in macrophages. J Cell Biol 2009; 186: 255-268.
101. Chiramel AI, Brady NR, Bartenschlager R. Divergent roles of autophagy in virus infection. Cells 2013; 2: 83-104.
102. Lee YR, Wang PS, Wang JR, Liu HS. Enterovirus 71-induced autophagy increases viral replication and pathogenesis in a suckling mouse model. J Biomed Sci 2014; 21: 80.
103. Kudchodkar SB, Levine B. Viruses and autophagy. Rev Med Virol 2009; 19: 359-378.
104. Sanjuan MA, Dillon CP, Tait SW, Moshiach S, Dorsey F, Connell S et al. Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. Nature 2007; 450: 1253-1257.
105. Gutierrez MG, Munafo DB, Beron W, Colombo MI. Rab7 is required for the normal progression of the autophagic pathway in mammalian cells. J Cell Sci 2004; 117: 2687-2697.
106. Garciá-Dorival I, Wu W, Dowall S, Armstrong S, Touzelet O, Wastling J et al. Elucidation of the Ebola virus VP24 cellular interactome and disruption of virus biology through targeted inhibition of host-cell protein function. J Proteome Res 2014; 13: 5120-5135.
107. Sakurai Y, Kolokoltsov AA, Chen CC, Tidwell MW, Bauta WE, Klugbauer N et al. Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. Science 2015; 347: 995-998.
108. Pereira GJ, Hirata H, Fimia GM, do Carmo LG, Bincoletto C, Han SW et al. Nicotinic acid adenine dinucleotide phosphate (NAADP) regulates autophagy in cultured astrocytes. J Biol Chem 2011; 286: 27875-27881.
109. Gong K, Chen C, Zhan Y, Chen Y, Huang Z, Li W. Autophagy-related gene 7 (ATG7) and reactive oxygen species/extracellular signal-regulated kinase regulate tetrandrine-induced autophagy in human hepatocellular carcinoma. J Biol Chem 2012; 287: 35576-35588.
110. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014; 371: 1418-1425.
111. Yazdanpanah Y, Arribas JR, Malvy D. Treatment of Ebola virus disease.Intensive. Care Med 2015; 41: 115-117.
112. Ippolito G, Feldmann H, Lanini S, Vairo F, Di Caro A, Capobianchi MR et al. Viral hemorrhagic fevers: advancing the level of treatment. BMC Med 2012; 10: 31.
113. Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother 2014; 69: 2123-2131.
114. Qiu P, Cui X, Barochia A, Li Y, Natanson C, Eichacker PQ. The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death. Expert Opin Investig Drugs 2011; 20: 1555-1564.
115. Ma Y, Wen X, Peng J, Lu Y, Guo Z, Lu J. Systematic review and meta-analysis on the association between outpatient statins use and infectious disease-related mortality. PLoS One 2012; 7: e51548.